The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/89432

Please be advised that this information was generated on 2019-03-25 and may be subject to change.
Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion

Karin G. Gerritsen,1 Hilde P. Peters,2 Tri Q. Nguyen,1 Maarten P. Koeners,3 Jack F. Wetzels,2 Jaap A. Joles,3 Erik I. Christensen,1 Pierre J. Verrout,5 Dongxia Li,6 Noelynn Oliver,6 Leon Xu,6 Robbert J. Kok,7 and Roel Goldsmeding1

Departments of 1Pathology and 3Nephrology, University Medical Center Utrecht, Utrecht; 2Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen; 7Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands; 4Section of Cell Biology, Department of Anatomy, Aarhus University, Aarhus, Denmark; 5Institut de la Vision, Institut National de la Santé et de la Recherche Médicale Unité 968, Paris, France; and 6FibroGen, Incorporated, San Francisco, California

MATERIALS AND METHODS

Recombinant CTGF proteins and anti-CTGF antibodies. Recombinant CTGFs and anti-CTGF antibodies were supplied by FibroGen (San Francisco, CA). The recombinant human CTGFs were produced in a baculovirus expression system in Chinese Hamster Ovary cell lines cultured in hollow-fiber fermentors. The proteins were purified by CTGF-affinity and cation exchange chromatography. Recombinant full-length CTGF comprised all four domains (Q27-A349), and the NH2-terminal fragment comprised domains 1 and 2 (Q27-A178).

Gelofusine. We purchased Gelofusine (40 g/l) from Braun (Oss, The Netherlands). Gelofusine is a modified gelatin consisting of polypeptides with an average molecular mass of 30 kDa. In previous studies, we have shown that Gelofusine effectively blocks tubular reabsorption of low molecular mass proteins (30).

Animal experiments. Pharmacokinetic studies were performed in mice and rats. All experiments were approved by the Animal Ethical Commission of the University of Utrecht and performed in accordance with national guidelines for the care and handling of animals.
C57Bl/6j mice (12 wk old; Harlan, Horst, The Netherlands) received recombinant human CTGF by tail vein injection (single dose) or by intraperitoneal infusion (3 days) using micro-osmotic pumps (model 1003D; ALZET, Cupertino, CA). To evaluate the plasma disappearance and uptake in the kidneys, mice were killed at various time points after bolus injection of full-length CTGF or NH2-CTGF (12.5–50 pmol/g body wt). Kidneys were harvested, weighed, and processed for ELISA or immunohistochemistry, as described below. To evaluate the effects of inhibition of proximal tubular reabsorption, a separate group of mice received Gelofusine (40 g/l; Braun) either by tail vein injection (5 µl/g body wt) 1–2 min before NH2-CTGF injection in the other tail vein (n = 3) or by tail vein injection (10 µl/g body wt) during NH2-CTGF intraperitoneal infusion (0.6 pmol/min) by micro-osmotic pump 3 days after intraperitoneal implantation under isoflurane anesthesia (n = 3).

To identify the endocytic receptors involved in tubular reabsorption of (endogenous) CTGF, urine was collected during a 24-h period from mice deficient for cubulin or megalin/cubulin, obtained by crossing mice bearing floxed cubulin alleles or both cubulin and megalin floxed alleles with Moz2Cre mice. Surviving offspring exhibited a mosaic pattern of cubulin deficiency or megalin and cubulin deficiency (11). Deletion of cubulin and megalin varied from 70% to over 95%. Age-matched wild-type mice were used as controls. Endogenous uCTGF levels were determined by ELISA as described below.

Studies in rats were performed to quantify the renal extraction and fractional excretion (FE). Male Wistar-Kyoto rats (15–17 wk old; Harlan) were anesthetized with intraperitoneal pentobarbital sodium (72 mg/kg). The trachea was intubated with a 16-G catheter (Veni-systems Abbcath-T; Abbott, Ireland). A PE-90 catheter was placed in the left jugular vein for infusion of solutions, a second PE-10 catheter was introduced for CTGF infusion, and a third PE-10 catheter for supplemental anesthesia. The left femoral artery was cannulated with PE-90 tubing for blood withdrawal and pressure monitoring. A PE-90 catheter was placed in the bladder for urine collection. The left renal vein was exposed through a ventral midline and left subcostal incision, to make it accessible for puncture. During surgery, animals received intravenous infusion of 0.9% NaCl and 6% BSA followed by 1% BSA after 20 min at a rate of 8 ml/kg·h·1. Following surgery, the infusion rate was reduced to 6 ml/kg·h·1 and maintained throughout the experiment. The solution also contained 30 mM Inulin (Inuest; Fresenius Pharma, Linz, Austria) and 25 mM para-aminohippuric acid (PAH; Sigma, St. Louis, MO) for clearance measurements. After a 45-min stabilization period, infusion of full-length CTGF or NH2-CTGF was started at 54 or 7 pmol·kg−1·min−1, respectively, based on pilot clearance studies. Urine was collected at 15-min intervals. After the start of CTGF infusion (90 min), two arterial blood samples were taken at an interval of 30 min to determine fractional CTGF excretion. After a short equilibration period, a third arterial blood sample was taken simultaneously with puncture of the left renal vein to determine renal extraction ratios and tubular uptake. Inulin and PAH were measured as described (32).

Human studies. Effect of impairment of tubular reabsorption on uCTGF excretion was studied in healthy human volunteers by infusion of Gelofusine and in renal disease patients with varying degrees of tubular dysfunction. The Gelofusine protocol was approved by the Ethics Review Committee of the University Medical Center St. Radboud, and informed consent was obtained from healthy volunteers. In accordance with Dutch ethical regulations, all patients consented that blood and urine samples were used for medical research. The studies were conducted according to the principles of the Declaration of Helsinki.

Three healthy volunteers received infusion of Gelofusine (40 g/l; Braun), which was started at a rate of 10 ml/min for 5 min followed by 3 ml/min during 55 min. CTGF levels were measured in urinary samples taken before the infusion and at 30, 60, and 180 min after the start of the infusion and in blood samples drawn before and at the end of Gelofusine infusion.

In a cross-sectional study, 108 patients with renal impairment due to glomerular diseases were enrolled from March 1995 through March 2004 at the Department of Nephrology, Radboud University Nijmegen Medical Center (The Netherlands). Details of the cross-sectional study have been described (4).

CTGF ELISA. CTGF levels in plasma, urine, and renal homogenates were determined by sandwich ELISA, using specific antibodies (FibroGen) directed against distinct epitopes in the NH2-terminal fragment of CTGF, detecting both full-length CTGF and the NH2-fragment. Frozen renal tissue (stored at −80°C) was homogenized in lysis buffer (20 mM Tris [Roche, Mannheim, Germany], 150 mM NaCl (Merck, Darmstadt, Germany), 1% Triton X-100, 10% glycerol, 1 mM EDTA (Riedel-de Haen, Seelze, Germany), 0.1% SDS (Research Organics, Cleveland, OH), 1 mM EGTA, 0.5% sodium deoxycholate, 50 mM NaF, and 2 mM sodium orthovanadate (Sigma), pH 7.4) containing 5% Protease Inhibitor Cocktail (Sigma). The following two ELISAs were used: a human CTGF assay for detection of endogenous CTGF in human samples or recombinant human CTGF in rodent samples and a rodent CTGF assay for determination of endogenous CTGF in transgenic mice. For the human CTGF assay, microtiter plates (Maxisorb; Nunc, Roskilde, Denmark) were coated with capture anti-CTGF monoclonal antibody (5 µg/ml; FibroGen). Subsequently, diluted samples and standards (recombinant human CTGF; FibroGen) were added and incubated with non-cross-blocking human anti-CTGF monoclonal antibody conjugated directly to alkaline phosphatase (0.5 µg/ml; FibroGen). Para-nitrophenylphosphate (Sigma) was used as substrate for the colorimetric reaction. For the rodent CTGF assay, a similar protocol was applied: goat anti-NH2-CTGF polyclonal antibody (7.5 µg/ml; FibroGen) was used for coating, and a non-cross-blocking human anti-CTGF monoclonal antibody was used for detection, followed by incubation with goat anti-human IgG polyclonal antibody conjugated to alkaline phosphatase (1:2,000; Sigma). Recombinant mouse CTGF (FibroGen) was used for standard curves. Assay sensitivities (lower limits of detection) were 0.02 pmol/ml for the human CTGF assay and 0.04 pmol/ml for the rodent CTGF assay. The antibody used for detection in the human CTGF assay does not cross-react with rodent CTGF. Intra- and interassay coefficients of variation were within 10%. Plasma levels of endogenous CTGF in healthy rodents, healthy human subjects, and renal disease patients are shown in Supplemental Table 1 (Supplemental data for this article may be found on the American Journal of Physiology: Renal Physiology website.).

In addition to the ELISAs detecting both full-length CTGF and the NH2-fragment, we applied the sandwich ELISA technique to specifically detect full-length CTGF by using two distinct antibodies directed against the COOH-terminal and NH2-terminal fragment. We did not measure significant amounts of full-length CTGF in human or rodent urine, neither in the healthy situation nor in the case of impaired tubular reabsorption, which is in accordance with previous reports (6, 12, 19, 27).

Immunofluorescence. Immunostaining for CTGF was performed on 3 µm formalin-fixed paraffin-embedded (FFPE) tissue sections. After deparaffinization, antigen retrieval was performed by predigestion with Protease XXIV (0.2 M phosphate; Sigma) followed by blocking of endogenous peroxidase activity (1% H2O2 in phosphatecitrate buffer). Sections were incubated with CTGF-specific human monoclonal antibody (FibroGen) (24 µg/ml in PBS/1% BSA) for 1 h followed by incubation with 24Bb anti-human IgG (1:100, 30 min) (Dako, Glostrup, Denmark). Amplification was performed with Powervision peroxidase goat anti-rabbit IgG (Klinipath, Duiven, The Netherlands) (30 min) and FITC Tyramide Amplification Reagent (1:50, 10 min) (PerkinElmer, Boston, MA). TO-PRO 3 Iodide (Molecular Probes, Eugene, OR) was used for nuclear counterstaining.

For double immunofluorescence staining for CTGF and megalin, 3 µm deparaffinized FFPE sections were pretreated by boiling in Tris-EDTA buffer, pH 9.0, and incubated with goat anti-rat megalin
polyclonal antibody (1:50) (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h followed by incubation with peroxidase-conjugated rabbit anti-goat IgG (1:50, 30 min) (Dako) and amplification with FITC Tyramide Amplification Reagent (1:50, 10 min) (PerkinElmer). Subsequently, sections were incubated with CTGF-specific human monoclonal antibody (24 μg/ml) (FibroGen) for 1 h followed by incubation with Alexa Fluor 647-conjugated goat anti-human IgG (1:50, 30 min) (Molecular Probes).

Slides were mounted in Vectashield (Vector Laboratories, Ontario, Canada) and visualized by confocal laser scanning microscopy. For all stainings, incubation with secondary antibody alone served as a negative control.

**Immunohistochemistry.** To identify proximal tubules, staining with *Lotus tetragonolobus* agglutinin (LTA) was applied (5, 28). Deparaffinized FFPE sections (3 μm) were pretreated by boiling in citrate buffer, pH 6.0, and incubated with horseradish peroxidase-conjugated LTA (Sigma) (1:32) for 1 h followed by incubation with NovaRed for 10 min (Vector Laboratories). Sections were counterstained with hematoxylin and visualized by a Nikon Eclipse E800 microscope (Nikon Netherlands, Lijnden, the Netherlands).

Consecutive sections were stained with LTA and anti-CTGF (see **Immunofluorescence**). Images of corresponding areas were merged by digital selection and coloring of LTA-positive areas using Adobe Photoshop software version 11.0 (Adobe Systems, San Jose, CA).

**Measurement of creatinine.** Urinary and serum creatinine were measured with enzymatic assays (JL Elitech, Labarthe-Inard, France) for murine samples, DiaSys (Holzheim, Germany) for rat samples, and Roche (Mannheim, Germany) for human samples (automated technique).

**Measurement of β2-M.** uβ2-M was measured by ELISA, as described before (18). To avoid degradation of uβ2-M, subjects ingested 4 g sodium bicarbonate on the evening before the test. β2-M was only measured in urine with a urinary pH >6.0.

**Calculations and statistics.** Data, expressed as means ± SE, were compared with Student’s t-test (2-tailed). Paired Student’s t-test was used for comparison of urinary concentrations in mice and FE in humans before and after Gelofusine administration. Statistical analyses of subsequent urinary concentrations during Gelofusine infusion in humans was performed by ANOVA for repeated measures. Correlations were assessed by linear regression. In the patient study, uCTGF, uβ2-M, plasma CTGF, and serum creatinine were logarthimically transformed before analysis because of their skewed distribution. Urinary concentrations were expressed in moles per gram of creatinine to correct for differences in urine dilution. GFR was estimated by the abbreviated Modification of Diet in Renal Disease equation (21). Renal clearances and FE were calculated by standard formulas. Renal extraction was calculated as follows:

\[
\text{artrial concentration} - \text{renal vein concentration} \div \text{artrial concentration} \times 100\% \quad (1)
\]

Tubular uptake was expressed as a percentage of the amount of CTGF extracted by the kidney and calculated as follows:

\[
\left(1 - \frac{\text{urine concentration} \times V}{\left(\text{artrial concentration} \times \text{ERPF} - \text{renal vein concentration} \times \text{ERPF} + V\right)}\right) \times 100\%
\]

where \(V\) is the urinary flow rate and ERPF the effective renal plasma flow.

**RESULTS**

**Plasma CTGF** is glomerularly filtered, almost completely reabsorbed by proximal tubules, and only minimally excreted in urine. First, we investigated the fate of recombinant human CTGF that was administered intravenously to healthy mice. Using recombinant human CTGF and human CTGF specific antibodies, we could distinguish between endogenous and exogenous CTGF and exclude contribution of locally produced CTGF to measured tissue levels. We administered both full-length CTGF and the NH2-terminal fragment but focused our analyses primarily on NH2-CTGF, since this is the predominant form detected in urine (6, 12, 19, 27). Intra-venous bolus injection of NH2-CTGF led to rapid accumulation in the renal cortex (Fig. 1A). Immunofluorescent staining showed abundant NH2-CTGF in endocytic vesicles in renal proximal tubular cells (Fig. 1, B-C). Localization in apical vesicles suggested that circulating NH2-CTGF was glomerularly filtered and subsequently reabsorbed from the luminal fluid. Recombinant full-length CTGF was also filtered and tubularly reabsorbed (Fig. 1D). LTA and CTGF staining of consecutive sections identified the CTGF-containing segments as proximal tubules (Fig. 2). Thus, in healthy mice, CTGF is glomerularly filtered and to a large extent endocytosed by proximal tubular cells.

To quantify renal extraction and FE, we performed additional experiments in anesthetized rats that received CTGF by continuous infusion. After reaching steady state, kinetic parameters were calculated from steady-state plasma concentrations and urinary excretion, as summarized in Table 1. For determination of renal extraction, blood samples were drawn simultaneously from the renal vein and femoral artery. Renal NH2-CTGF extraction was 21 ± 1%, which was 74% of that of insulin. For full-length CTGF, renal extraction was 18 ± 3%. Tubular uptake was almost complete, resulting in FEs of <1% (Table 1). Thus, in healthy rats, renally extracted CTGF is almost completely metabolized by the kidney and minimally excreted in the urine.

**Inhibition of tubular reabsorption reduces renal CTGF uptake and increases uCTGF excretion.** We next studied the effect of tubular reabsorption impairment on uCTGF. Gelofusine, a modified gelatin clinically applied as a plasma volume expander, was used to inhibit proximal tubular reabsorption (13, 30). In mice, intravenous injection of Gelofusine 1–2 min before intravenous bolus injection of NH2-CTGF reduced cortical NH2-CTGF uptake by 49 ± 11% (\(P < 0.05\); Fig. 3A). Pretreatment with Gelofusine resulted in a comparable decrease in cortical uptake of full-length CTGF (Supplemental Figure). Moreover, a single intravenous bolus dose of Gelofusine during continuous NH2-CTGF infusion by an intraperitoneal miniosmotic pump in mice increased urinary NH2-CTGF 15 ± 1-fold (\(P < 0.05\); Fig. 3B).

In addition to experiments with recombinant CTGFs in mice, we also studied the effect of inhibition of tubular reabsorption on urinary excretion of endogenous CTGF in healthy human volunteers. Although basal levels were low, Gelofusine infusion induced a 23 ± 1-fold increase in uCTGF (\(P < 0.01\)), which was paralleled by an increase in urinary β2-microglobulin (uβ2-M) (\(r = 0.99\)) (Fig. 4, A and B). FE of CTGF increased from 0.47 ± 0.1 to 13 ± 3% (\(P < 0.05\)). These results demonstrate that, in healthy subjects, diminished tubular re-uptake of CTGF from the luminal fluid is sufficient to induce a significant increase of uCTGF.

In renal disease, elevated uCTGF is tightly associated with tubular dysfunction. To investigate whether uCTGF in renal disease correlated with urine levels of uβ2-M as a marker of tubular dysfunction, we analyzed urines of 108 patients with renal impairment resulting from glomerular diseases. The patients had varying degrees of tubular dysfunction, as indicated
by a wide range of u\(\beta_2\)M levels. General characteristics are summarized in Supplemental Table 2. We observed a tight correlation between \(uCTGF\) and \(u\beta_2M\) \((r = 0.85, P < 0.001;\) Fig. 5). \(u\beta_2M\) emerged as the only independent determinant of \(uCTGF\) \((\beta = 0.81, P < 0.001)\) in a multiple linear regression model containing age, estimated GFR (or serum creatinine), and plasma CTGF, which were all significantly associated with \(uCTGF\) in univariate analysis. This is strong evidence that...

---

**Fig. 1.** Renal CTGF accumulation after single-dose iv administration of recombinant human CTGF in mice. A: estimated renal NH\(_2\)-CTGF (N-CTGF) levels at different time points after injection, determined by ELISA. Each dot represents one animal. Curve fitting, performed with GraphPad Prism, was by the one-phase exponential decay model. B–D: immunofluorescence of C57Bl/6J kidney by using human anti-CTGF (green) and TO-PRO 3 Iodide for nuclear staining (red), visualized by confocal laser scanning microscopy. B: N-CTGF-treated animal at 10 min showing abundant N-CTGF in proximal tubules, intensely staining the brush border. Magnification \(\times630\). C: N-CTGF-treated animal at 30 min showing abundant N-CTGF positive apical endocytic vesicles in proximal tubular cells. Magnification \(\times1,000\). D: CTGF-treated animal at 6 min showing CTGF in proximal tubules. Magnification \(\times630\). E: saline-treated animal. Magnification \(\times630\).

**Fig. 2.** Colocalization of N-CTGF and *Lotus tetragonobolus* agglutinin (LTA), a proximal tubule marker. Consecutive sections of mouse kidney after iv administration of recombinant human N-CTGF were stained with human anti-CTGF (green) and LTA (red). CTGF-positive endocytic vesicles are located exclusively in LTA-positive proximal tubules. Original magnification \(\times200\).
tubular dysfunction is a major determinant of the uCTGF increase in renal disease.

**Megalin is involved in proximal tubular reabsorption of CTGF.** To identify the endocytic receptor involved in the proximal tubular reabsorption of CTGF, we studied uCTGF in transgenic mice with deficiencies of the endocytic receptors megalin and/or cubilin. These multiligand receptors are known to be responsible for tubular reabsorption of most of the filtered proteins (7). In MOX2-Cre transgenic mice with a mosaic expression pattern of megalin and cubilin in the kidney, exhibiting combined deficiency of both receptors, uCTGF was very high (14/11006 1.5 nmol/g creatinine), whereas, in cubilin knockout and wild-type mice, uCTGF levels were below the level of quantification. There were no differences in plasma CTGF between these various mouse strains. Immunofluorescent staining after intravenous administration of CTGF in healthy C57Bl/6J mice revealed colocalization of megalin and CTGF in the cortical (proximal) tubules (Fig. 6). These results show that proximal tubular endocytosis of CTGF is mediated by the multiligand receptor megalin.

**DISCUSSION**

The main finding of our studies is that failure of proximal tubular reabsorption is a major determinant of increased uCTGF. In healthy animals, intravenously administered CTGF was filtered in the glomerulus, but only minimal excretion in the urine was observed. This was found to be due to almost

### Table 1. Renal handling parameters of recombinant human CTGF in healthy rats

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NH2-Fragment</th>
<th>Full-Length CTGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Body wt, g</td>
<td>323 ± 28</td>
<td>309 ± 11</td>
</tr>
<tr>
<td>Mean arterial pressure, mmHg</td>
<td>92 ± 7</td>
<td>101 ± 2</td>
</tr>
<tr>
<td>GFR, ml·kg⁻¹·min⁻¹ (inulin)</td>
<td>7.8 ± 0.5</td>
<td>9.0 ± 0.1</td>
</tr>
<tr>
<td>Renal plasma flow, ml·kg⁻¹·min⁻¹ (PAH)</td>
<td>30 ± 4</td>
<td>30 ± 1</td>
</tr>
<tr>
<td>Renal extraction, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inulin</td>
<td>29 ± 2</td>
<td>25 ± 2</td>
</tr>
<tr>
<td>CTGF</td>
<td>21 ± 0.7</td>
<td>18 ± 3</td>
</tr>
<tr>
<td>Tubular uptake of CTGF, % of extracted amount</td>
<td>90.9 ± 0.02</td>
<td>99.96 ± 0.004</td>
</tr>
<tr>
<td>Fractional excretion of CTGF, %</td>
<td>0.10 ± 0.02</td>
<td>0.025 ± 0.006</td>
</tr>
</tbody>
</table>

Values are means ± SE; n, no. of rats. CTGF, connective tissue growth factor; GFR, glomerular filtration rate; PAH, para-aminohippuric acid.

---

**Fig. 3. Effect of inhibition of proximal tubular reabsorption by Gelofusine in mice.**

A: estimated renal levels of recombinant human N-CTGF 10–15 min after iv N-CTGF administration in mice. Gelofusine administration before N-CTGF injection (n = 3) reduced renal N-CTGF accumulation compared with saline pretreatment (n = 3) (P = 0.03, unpaired t-test). Gelofusine administration did not affect plasma N-CTGF levels. B: urinary N-CTGF levels during continuous infusion of recombinant human N-CTGF by ip miniosmotic pump in 3 mice before (16 h urine collection) and within 1 h after iv administration of Gelofusine bolus injection. Urinary N-CTGF increased from 0.22 ± 0.03 to 3.4 ± 0.7 nmol/g creatinine (P = 0.04; paired t-test).

**Fig. 4. Effect of inhibition of proximal tubular reabsorption by Gelofusine in humans.**

A: Gelofusine infusion for 60 min in 3 healthy volunteers (▲, ●, ■) induced a 23 ± 1-fold increase in urinary CTGF (uCTGF) (P = 0.004; repeated-measures ANOVA) that was paralleled by an increase in urinary β₂-microglobulin (uβ₂M). B: uCTGF and uβ₂M were tightly correlated before, during, and after Gelofusine infusion.

---

**Fig. 6.** Immunofluorescent staining of megalin and CTGF in the kidney of healthy C57Bl/6J mice. Megalin and CTGF are colocalized in the proximal tubules (Fig. 6). These results show that proximal tubular endocytosis of CTGF is mediated by the multiligand receptor megalin.
complete reabsorption in proximal tubular cells by megalin-mediated endocytosis.

Our data show that both full-length and the NH2-CTGF fragment are similarly handled by the kidney. For both CTGFs, we observed extensive proximal tubular uptake in apical endocytic vesicles, very low FE (<1%), and almost complete tubular uptake of extracted CTGF (>99%). We focused our analyses on the NH2-terminal fragment of CTGF since this is the predominant CTGF peptide in urine (6, 12, 19, 27) and because the biomarker potential of CTGF has been studied most extensively for this proteolytic fragment (1, 2, 6, 10, 12, 19, 24, 25, 27).

After intravenous administration in rats, renal extraction of circulating NH2-CTGF was 74% of that of inulin. Because we found no immunohistochemical evidence for basolateral uptake in proximal tubular epithelial cells, we assume that most of the extracted NH2-CTGF was filtered in the primary urine by glomerular sieving, which would imply a sieving coefficient of ~0.7. This is consistent with the observation that proteins smaller than 20 kDa have sieving coefficients >0.5 (22). The high degree of tubular reabsorption of filtered NH2-CTGF and low FE are also in accordance with previously observed values for other low molecular mass proteins, e.g., β2M (fractional reabsorption 99.97%, FE 0.03%) and lysozyme (FE 0.4%) (3, 20, 33).

Impairment of proximal tubular reabsorption, either induced by Gelofusine administration or in human renal disease, was consistently associated with an increase in uCTGF excretion in close correlation with that of β2M. Tubular dysfunction is an important parameter in the assessment of renal damage. In CKD, the degree of tubulointerstitial damage and the amount of low molecular mass proteinuria are better predictors of functional outcome than the severity of glomerular damage or the total amount of proteinuria (8, 9). In DN, low molecular mass proteinuria was found even before the occurrence of microalbuminuria, probably representing a sign of incipient DN (9, 15). Our results imply that uCTGF, reflecting proximal tubular dysfunction, may be a valuable prognostic marker in renal disease. Moreover, in contrast to known proximal tubular dysfunction markers such as the biologically inert β2M and α1-microglobulin, luminal accumulation of CTGF and its fragments might contribute actively to the pathogenic process (14, 23). Consistent with such a concept, uCTGF predicted progression of microalbuminuria in diabetic patients (29), and, in another study, uCTGF independently predicted deterioration of renal function in patients with iMN (1). However, the true clinical value of uCTGF in renal disease still needs to be established.

Although we show that uCTGF is highly dependent on tubular function and tightly associated with uβ2M, the correlation between the two proteins is not absolute ($r^2 = 0.72$). This might reflect disease-associated regulation of CTGF production, either systemically or locally in different segments of the nephron (16, 31). As expected for a filtered solute, plasma CTGF was correlated with uCTGF in univariate analysis. However, it did not emerge as an independent determinant in multivariate analysis. The relative contribution of increased local CTGF production could not be determined because the
filtered load was unknown. Considering the virtually complete proximal reabsorption from the primary urine in the healthy kidney, CTGF produced in the glomeruli and released in the luminal fluid will have limited impact on uCTGF as long as the proximal endocytic apparatus is intact. On the other hand, luminal secretion of CTGF expressed in distal tubules would be expected to considerably affect uCTGF levels, but the linearity of the relationship between uβ2M and uCTGF indicates that tubular dysfunction is the major determinant of uCTGF in the renal diseases included in our survey. However, the relative contribution of increased local synthesis on uCTGF in specific renal diseases remains to be elucidated in future studies.

In conclusion, CTGF is reabsorbed almost completely from the glomerular filtrate in proximal tubules via megalin-mediated endocytosis in the healthy kidney, and elevated uCTGF may largely reflect proximal tubular dysfunction. This should be taken into account when using uCTGF as a biomarker and in experimental work addressing its pathogenic involvement in CKD.

ACKNOWLEDGMENTS

We thank Marcel Fens, Dionne van der Giezen, Willemiek Kassing-van der Ven, Arianne van Koppen, Jan Willem Leeuwis, Paula Martens, Pia Nielsen, Ebel Pieters, and Kevin van der Ven for technical assistance and support.

DISCLOSURES

This study was supported by a grant from FibroGen, Inc., a company interested in commercializing anti-CTGF therapies. R. Goldschmeding has been employed by and has received research support from FibroGen. L. Xu and N. Oliver have been employed by and own stock options in FibroGen. D. Li is employed by and owns stock options in FibroGen.

REFERENCES


AJP-Renal Physiol • VOL 298 • JUNE 2010 • www.ajrenal.org
